Pharmaceutical and Life Sciences Deals Insights Quarterly

February 2014
  • Print-friendly version
Pharmaceutical and Life Sciences Deals Insights Quarterly

At a glance

Deal activity in the fourth quarter represented a 24% increase in volume and a 102.8% increase in value relative to the third quarter of 2013. Relative to the fourth quarter of 2012, deal volume declined by 29.5%; however, deal value represented an increase of 106.8%. On an annual basis, deal volume in 2013 represented a modest decline of 11.6%, while deal value increased 45.8% relative to 2012. The increase in deal value in 2013 is due primarily to two initial public offerings (IPOs) in the first quarter of 2013 and a particularly strong fourth quarter.

This issue of Pharmaceutical and Life Sciences Deals Insights Quarterly brings you PwC’s perspective on deal activity in the industry and features the following:

Market update: A summary of M&A deals and trends for the previous quarter.

Market spotlight: This issue focuses African countries which represent some of the world’s fastest-growing economies, and have an increased focus on consumer-oriented sectors and investment in the pharmaceutical and life sciences industry.

Strategy corner: Tips and insights on different aspects of deal making; tax planning is a critical component of deal integration and can provide substantial cash savings to acquires.

Further reading:

US Pharmaceuticals and Life Sciences Deals Insights Quarterly Q3 2013

US Pharmaceuticals and Life Sciences Deals Insights Quarterly Q2 2013

US Pharmaceuticals and Life Sciences Deals Insights Quarterly Q1 2013

US Pharmaceuticals and Life Sciences Deals Insights Quarterly Q4 2012